- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05941299
Clinical Trial to Demonstrate the Safety and Performance of REGENERA Breast Implant in 40-70 Years Old Women Affected by Malignant Breast Lesion Treated by Lumpectomy
April 10, 2024 updated by: Tensive SRL
A Pivotal Study of REGENERA Implant in Malignant Breast Lesion Treated by Lumpectomy
The goals of this clinical trial are:
- demonstrate the safety of REGENERA breast implant in patients undergoing lumpectomy of malignant breast lesions
- demonstrate the safety and performance of REGENERA in terms of investigator's satisfaction, potential interference with current standard-of-care imaging techniques and occurrence of device-related serious adverse events.
Participants will perform 13 study visits, and at each visit, all necessary study procedures will be performed according to the clinical investigation plan:
- Screening
- Pre-surgery treatment
- Surgery and study device implant
- Post-surgery follow-up up to 5 years
Study Overview
Status
Recruiting
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
92
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Margherita Tamplenizza
- Phone Number: +39 0256660185
- Email: margherita.tamplenizza@tensivemed.com
Study Locations
-
-
-
Milan, Italy, 20141
- Recruiting
- Ieo Istituto Europeo Di Oncologia
-
Contact:
- Mario Rietjens
-
Pisa, Italy, 56126
- Recruiting
- A.O.U. Pisana - Ospedale Santa Chiara
-
Contact:
- Manuela Roncella
-
-
-
-
-
A Coruña, Spain, 15001
- Recruiting
- Complejo Hospitalario Universitario A Coruna
-
Contact:
- Benigno Acea Nebril
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Female adult subject aged 40-70 years.
- Subject diagnosed with malignant breast lesion:
- monolateral nodular infiltrative carcinoma,
- without microcalcification,
- single or multifocal,
- included in an area with a maximum diameter of 4 cm,
- non-metastatic (M0).
- Subject with clinically negative axilla.
- Subject considered eligible for conservative breast surgery - BCS (Breast-Conserving Surgery, lumpectomy or quadrantectomy), leaving a volume deficit compatible with a REGENERA implant (available in two dried sizes) volume of 70 ml or 100 ml.
- Confirmation of malignant lesion (pT1, pT2, pN0, pN1) with no discordance between biopsy and radiological imaging.
- Adequate hematopoietic functions.
- Good general health and mentally sound.
- Subject able and willing to give written informed consent form.
Exclusion Criteria:
- Subject with actual concomitant benign breast lesion (B2 and B3), unless present in the same mammary quadrant or in the contralateral breast.
- Subject with actual concomitant malignancies, lobular neoplasm, metastatic breast carcinoma, sarcoma, malignant phyllodes lesions, or Paget's disease.
- Axillary dissection planned as part of the breast lesion surgery.
- History of surgery, chemotherapy, neoadjuvant chemotherapy, or irradiation of the breast parenchyma object of the study.
- Skin retraction at the breast to be operated.
- Infection of the surgical site confirmed pre-operatively by clinical examination.
- Abnormal blood sugar and glycosylated hemoglobin.
- Hard smoker (more than 10 cigarettes a day).
- Acute or chronic severe renal insufficiency (creatinine values >180 μmol/l).
- History of severe asthma or allergies (including allergy to anesthetics or contrast media).
- Autoimmune disease.
- Subjects who are known to be carriers of BCRA mutation.
- Inability to undergo MRI or allergy to contrast media.
- Systemic infections in an active phase.
- Immunocompromised patients (HIV).
- Pregnant or breastfeeding woman or woman who has nursed a child within 3 months prior to enrolment in the study.
- Subject who has participated in another interventional study within the past 3 months.
- Subject who received immunosuppressant therapy in the last 3 months.
- History of substance abuse (drug or alcohol).
- Non-collaborative patients (severe physical disabilities or psychiatric disorders, as per specialist opinion).
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: REGENERA breast implant implantation
|
Each patient will perform 13 study visits, and at each visit, all necessary study procedures will be performed according to the clinical investigation plan:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rate of adverse events (AEs) with a causal relationship to REGENERA at 3 months.
Time Frame: 3 months
|
The rate of AEs with a causal relationship to REGENERA should be <5% at 3 months after implant.
|
3 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean investigator's satisfaction on the implanting procedure at 1week.
Time Frame: 1 week after implant
|
At least 7 in a 0-10 Visual Analogue Scale, VAS.
|
1 week after implant
|
Mean investigator's satisfaction on REGENERA usability during surgery at 1 week.
Time Frame: 1 week after implant
|
At least 40 in an "ad hoc" questionnaire (12-60 scale).
|
1 week after implant
|
Mean investigator's satisfaction on overall surgical procedure and clinical outcome of the patient at 12 months.
Time Frame: 12 months
|
At least 7 in a 0-10 Visual Analogue Scale, VAS.
|
12 months
|
Number of interference events of REGENERA with ultrasound imaging technique, through the completion of a questionnaire by the investigators.
Time Frame: After 6 and 12 months
|
An imaging evaluation questionnaire will be provided for investigators to fill out.
|
After 6 and 12 months
|
Number of interference events of REGENERA with mammography imaging technique, through the completion of a questionnaire by the investigators.
Time Frame: After 12 months
|
An imaging evaluation questionnaire will be provided for investigators to fill out.
|
After 12 months
|
Number of interference events of REGENERA with MRI (with and without contrast) imaging technique, through the completion of a questionnaire by the investigators.
Time Frame: After 6 and 18 months
|
An imaging evaluation questionnaire will be provided for investigators to fill out.
|
After 6 and 18 months
|
Rate of serious adverse events (SAEs) with a causal relationship to REGENERA after 3 months and up to 18 months.
Time Frame: After 3 months and up to 18 months
|
The rate of REGENERA-related SAEs should be <5% at each follow-up after 3 months and up to 18 months.
|
After 3 months and up to 18 months
|
Rate of SAEs with a causal relationship to REGENERA after 18 months and up to 5 years.
Time Frame: After 18 months and up to 5 years
|
The rate of REGENERA-related SAEs should be <7% at each follow-up after 18 months and up to 5 years.
|
After 18 months and up to 5 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 29, 2023
Primary Completion (Estimated)
December 31, 2024
Study Completion (Estimated)
December 30, 2029
Study Registration Dates
First Submitted
June 16, 2023
First Submitted That Met QC Criteria
July 11, 2023
First Posted (Actual)
July 12, 2023
Study Record Updates
Last Update Posted (Actual)
April 11, 2024
Last Update Submitted That Met QC Criteria
April 10, 2024
Last Verified
February 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Tens-BBC/003/2021
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Neoplasm Malignant Female
-
Istituti Clinici Scientifici Maugeri SpACompletedFemale | Neoplasm Malignant | BreastItaly
-
National Cancer Institute (NCI)RecruitingAnatomic Stage III Breast Cancer AJCC v8 | Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Anatomic Stage IV Breast Cancer AJCC v8 | Advanced Malignant Solid Neoplasm | Locally Advanced Malignant Solid Neoplasm | Unresectable Malignant Solid... and other conditionsUnited States, Puerto Rico
-
University of Colorado, DenverCompletedMalignant Neoplasm of Female BreastUnited States
-
Mayo ClinicNational Cancer Institute (NCI)CompletedMalignant Solid Neoplasm | Breast Carcinoma | Digestive System Neoplasm | Skin Carcinoma | Malignant Female Reproductive System Neoplasm | Metastatic Malignant Neoplasm of Unknown Primary | Malignant Head and Neck Neoplasm | Malignant Brain Neoplasm | Malignant Central Nervous System Neoplasm | Malignant... and other conditionsUnited States
-
King Hussein Cancer CenterRecruiting
-
Erasme University HospitalUniversity Hospital, LilleRecruitingBreast Neoplasm Malignant FemaleFrance, Italy, Belgium
-
Celcuity, Inc.AvailableBreast Neoplasm Malignant FemaleUnited States
-
Centre Antoine LacassagneCerbalianceRecruitingBreast Neoplasm Malignant FemaleFrance, Monaco
-
National Cancer Institute (NCI)Active, not recruitingAdvanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | HER2-Positive Breast CarcinomaUnited States
-
National Cancer Institute (NCI)RecruitingAdvanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Triple-Negative Breast CarcinomaUnited States
Clinical Trials on REGENERA breast implant implantation
-
Mentor Worldwide, LLCWithdrawnAugmentation | Augmentation Revision | General Breast Enlargement | Post-lactational Involution | AsymmetryUnited States
-
Ideal Implant IncorporatedCompletedBreast ImplantsUnited States
-
Mentor Worldwide, LLCTerminated
-
Groupe SEBBINRecruiting
-
Seoul National University HospitalHansBiomed Co.,Ltd.Active, not recruitingBreast CancerKorea, Republic of
-
Clinique Saint François, Nice, FranceRecruitingOsteoarthritis Thumb | Osteoarthritis FingerFrance
-
Istituti Clinici Scientifici Maugeri SpACompletedBreast Cancer | Radiotherapy Side Effect | Breast Implant; Complications | Breast Implant ProtrusionItaly
-
Mentor Worldwide, LLCActive, not recruitingBreast Reconstruction, Revision Breast ReconstructionUnited States
-
Mashhad University of Medical SciencesCompletedAtrophy of Edentulous Alveolar Ridge | Alveolar Ridge AugmentationIran, Islamic Republic of
-
Cho Ray HospitalCommonwealth Scientific and Industrial Research Organisation, Australia; 3...RecruitingBone Loss | Defect LimbVietnam